A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

Trial Profile

A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Ranibizumab (Primary) ; Dexamethasone
  • Indications Branch retinal vein occlusion; Retinal oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms COMRADE-B
  • Sponsors Novartis
  • Most Recent Events

    • 03 Jun 2014 New source identified and integrated, European Clinical Trials Database record (EudraCT2011-001019-30).
    • 03 Jun 2014 New trial record
    • 12 May 2014 Primary endpoint 'Best-corrected-visual-acuity' has been met according to the Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top